1. Riethmuller G, Holz E, Schlimok G, et al.: Monoclonal antibody therapy for resected Dukes’ C colorectal cancer: Seven-year outcome of a multicenter randomized trial. J Clin Oncol 1998, 16:1788–1794. Report from a study of monoclonal antibody therapy for resected Dukes’ C colon cancer at 7 years, demonstrating a favorable response for patients in the treatment arm. Phase III trials are underway in the United States and Europe to confirm these results and, in addition, to assess the combination of antibody 17-1A and 5-FU chemotherapy regimens.
2. Gruber Rudolf, Leonardus JM, van Haarlem SO, et al.: The human antimouse immunoglobulin response and the anti-idiotypic network have no influence on clinical outcome in patients with minimal residual colorectal cancer treated with monoclonal antibody CO17-1A. Cancer Res 2000, 60:1921–1926.
3. Sears HF, Herlyn D, Steplewski A, Koprowski H: Phase II clinical trial of murine monoclonal antibody cytotoxic for gastrointestinal adenocarcinoma. Cancer Res 1985, 45:5910–5913.
4. Weiner LM, Moldofsky PJ, Gatenby RA, et al.: Antibody delivery and effector cell activation in a phase II trial of recombinant a-interferon and murine monoclonal antibody CD17-1A in advanced colorectal carcinoma. Cancer Res 1988, 48:2568–2573.
5. Ragnhammar P, Fagerberg J, Frödin JE, et al.: Effect of monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma: long-lasting, complete remissions can be induced. Int J Cancer 1993, 53:751–758.